Get started
Author

Holly M. Alley

Observed names: Holly Alley, Holly M Alley
OpenAlex ID: A5063379905
Systematic identification of signaling pathways with potential to confer anticancer drug resistance
2014 · Colin A. Martz, Kathleen A. Ottina, et al. · Science Signaling · 191
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
2015 · Suzanne E. Wardell, Matthew J. Ellis, et al. · Clinical Cancer Research · 155
Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader
2015 · Suzanne E Wardell, Erik R Nelson, et al. · Endocrine Related Cancer · 115
PDF
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer
2017 · John D. Norris, Stephanie J. Ellison, et al. · Journal of Clinical Investigation · 56
PDF
PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation
2016 · Gray R. Anderson, Suzanne E. Wardell, et al. · Science Translational Medicine · 53
Lysine Auxotrophy Combined with Deletion of the SecA2 Gene Results in a Safe and Highly Immunogenic Candidate Live Attenuated Vaccine for Tuberculosis
2011 · Joseph Hinchey, Bo Y. Jeon, et al. · PLoS ONE · 45
PDF
CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC
2017 · James P. Stice, Suzanne E. Wardell, et al. · Molecular Cancer Research · 40
Validation of histone deacetylase 3 as a therapeutic target in castration‐resistant prostate cancer
2017 · Abigail B. McLeod, James P. Stice, et al. · The Prostate · 32
Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer
2016 · Julie A Pollock, Suzanne E Wardell, et al. · Nature Chemical Biology · 21
Supplementary Figure Legends from CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC
2023 · James P. Stice, Suzanne E. Wardell, et al.
Supplementary Figures 1-4 from CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC
2023 · James P. Stice, Suzanne E. Wardell, et al.
Supplementary Figures 1-4 from CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC
2023 · James P. Stice, Suzanne E. Wardell, et al.
PDF
Data from CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC
2023 · James P. Stice, Suzanne E. Wardell, et al.
Supplementary Figure Legends from CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC
2023 · James P. Stice, Suzanne E. Wardell, et al.
Data from CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC
2023 · James P. Stice, Suzanne E. Wardell, et al.
Supplemental figure 3 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
2023 · Suzanne E. Wardell, Matthew J. Ellis, et al.
Supplemental figure 2 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
2023 · Suzanne E. Wardell, Matthew J. Ellis, et al.
Supplemental figure 5 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
2023 · Suzanne E. Wardell, Matthew J. Ellis, et al.
Supplemental figure 1 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
2023 · Suzanne E. Wardell, Matthew J. Ellis, et al.
Supplemental figure 4 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
2023 · Suzanne E. Wardell, Matthew J. Ellis, et al.
Supplemental figure 1 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
2023 · Suzanne E. Wardell, Matthew J. Ellis, et al.
Supplemental figure 2 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
2023 · Suzanne E. Wardell, Matthew J. Ellis, et al.
Supplemental figure 4 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
2023 · Suzanne E. Wardell, Matthew J. Ellis, et al.
Supplemental figure 3 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
2023 · Suzanne E. Wardell, Matthew J. Ellis, et al.
Supplemental figure 5 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
2023 · Suzanne E. Wardell, Matthew J. Ellis, et al.
Works count: 28
Citation count: 708
H-index: 9
I10-index: 9
Year
Topic
Type